✦ LIBER ✦

A Budgetary Impact Analysis Model for Everolimus in the Treatment of ER+ HER2- Metastatic Breast Cancer in England and Wales

✍ Scribed by Taylor, M.; Lewis, L.; Vieira, J.; Chandiwana, D.

Book ID: 122238115
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 59 KB
Volume: 16
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2013.08.440

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN28 Budget Impact Analysis of Everolim

PCN28 Budget Impact Analysis of Everolimus for ER+, HER2- Metastatic Breast Cancer Patients in the United States

✍ Xie, J.; Diener, M.; De, G.; Wu, E.Q.; Namjoshi, M. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

A Cost-Utility Analysis of Everolimus Pl

A Cost-Utility Analysis of Everolimus Plus Exemestane for the Treatment of ER+ HER2- Metastatic Breast Cancer in the United Kingdom

✍ Taylor, M.; Lewis, L.; Vieira, J.; Chandiwana, D. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

PO58 EFFICACY AND SAFETY OF FIRST-LINE E

PO58 EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS PLUS LETROZOLE IN ER+ HER2− METASTATIC BREAST CANCER: A MULTI-CENTER, OPEN-LABEL, PHASE 2 TRIAL BOLERO-4

✍ Azevedo, Sergio; Bachelo, Thomas; Gradishar, William; Ringeisen, Francois; Brech 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Intrathecal administration of trastuzuma

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis

✍ Zagouri, Flora; Sergentanis, Theodoros N.; Bartsch, Rupert; Berghoff, Anna S.; C 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 348 KB

A phase 1 study of vinflunine in combina

A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer

✍ R. Paridaens, O. Rixe, M. C. Pinel, H. Wildiers… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 298 KB

Cost-effectiveness analysis of trastuzum

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t